当前位置:首页 >财报库 > 报告详情

默沙东Merck & Co. Inc.(MRK)2025年第二季度财报(10-Q)「NYSE」(英文版)(51页).pdf

上传人: 1****1 编号:923193 2025-09-24 51页 561.31KB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-QQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30,2025ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For th

2、e transition period from _ to _Commission File No.1-6571Merck&Co.,Inc.(Exact name of registrant as specified in its charter)New Jersey22-1918501(State or other jurisdiction of incorporation)(I.R.S.Employer Identification No.)126 East Lincoln AvenueRahwayNew Jersey07065(Address of principal executive

3、 offices)(zip code)(Registrants telephone number,including area code)(908)740-4000Not Applicable(Former name,former address and former fiscal year,if changed since last report.)Securities Registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on whic

4、h registeredCommon Stock($0.50 par value)MRKNew York Stock Exchange1.875%Notes due 2026MRK/26New York Stock Exchange3.250%Notes due 2032MRK/32New York Stock Exchange2.500%Notes due 2034MRK/34New York Stock Exchange1.375%Notes due 2036MRK 36ANew York Stock Exchange3.500%Notes due 2037MRK/37New York S

5、tock Exchange3.700%Notes due 2044MRK/44New York Stock Exchange3.750%Notes due 2054MRK/54New York Stock ExchangeIndicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or fo

6、r such shorterperiod that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,以下是Merck & Co., Inc. 2025年第二季度报告的简要概括: 1. **财务表现**:2025年第二季度净收入为44.28亿美元,较2024年同期的54.61亿美元有所下降。基本每股收益为1.76美元,较2024年同期的2.15美元有所下降。 2. **收入**:销售额为158.06亿美元,较2024年同期的161.12亿美元有所下降。 3. **研发和收购**:Merck继续进行研发和收购,包括2025年7月对专注于呼吸疾病的生物制药公司Verona Pharma的收购,以及与多家公司签订的许可和合作协议。 4. **合作伙伴关系**:Merck与AstraZeneca、Eisai、Bayer、Ridgeback Biotherapeutics、Daiichi Sankyo和Moderna等公司建立了多种合作和许可协议。 5. **重组**:Merck批准了一项新的重组计划(2025年重组计划),预计将产生约30亿美元的累计税前成本,以优化其业务和制造网络。 6. **衍生品和风险管理**:Merck使用衍生品来管理外汇风险和利率风险,包括使用远期合约和利率互换合约。
** 药企并购潮? 研发投入大增! ** 跨界合作,药企新动向!
客服
商务合作
小程序
服务号
折叠